levonorgestrel-releasing intrauterine system

DEVICE10 trials

Sponsors

St George's, University of London, M.D. Anderson Cancer Center, University of North Carolina, Chapel Hill, University of Southern California, Assiut University

Conditions

AdenomyosisAtypical Endometrial HyperplasiaEndometrial AdenocarcinomaEndometrial CancerEndometrial Carcinoma Stage IEndometrioid Endometrial CancerFIGO Grade 1 Endometrial Endometrioid AdenocarcinomaFIGO Grade 2 Endometrial Endometrioid Adenocarcinoma

Phase 2

Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer

Active, not recruitingNCT00788671

M.D. Anderson Cancer CenterAtypical Endometrial Hyperplasia, Stage IA Uterine Corpus Cancer AJCC v7, Stage IB Uterine Corpus Cancer AJCC v7 +2

Start: 2008-11-03End: 2027-11-30Updated: 2025-08-15

Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer

WithdrawnNCT01943058

University of Southern CaliforniaAtypical Endometrial Hyperplasia, Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma +8

Start: 2014-03-31End: 2017-10-31Updated: 2014-09-10

Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer

Active, not recruitingNCT02397083

M.D. Anderson Cancer CenterAtypical Endometrial Hyperplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma

Start: 2015-09-23End: 2028-09-30Updated: 2026-09-10

Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia

CompletedNCT05172999

Fudan UniversityAtypical Endometrial Hyperplasia, Fertility Issues, Obesity

Start: 2022-01-08End: 2026-02-28Updated: 2026-03-13

Medroxyprogesterone Acetate vs LNG-IUS in Early-stage Endometrioid Carcinoma and Atypical Hyperplasia Patients

Hua LiFertility Sparing

Start: 2022-11-01End: 2025-11-01Target: 148Updated: 2022-10-04

Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer

Not yet recruitingNCT07781150

Tongji HospitalAtypical Endometrial Hyperplasia, Endometrial Carcinoma Stage I, Endometrioid Endometrial Cancer +2

Start: 2026-11-01End: 2031-06-30Target: 128Updated: 2026-08-24

Phase 3

Intrauterine Levonorgestrel and Observation or Observation Alone in Preventing Atypical Endometrial Hyperplasia and Endometrial Cancer in Women With Hereditary Non-Polyposis Colorectal Cancer or Lynch Syndrome

TerminatedNCT00566644

St George's, University of LondonEndometrial Cancer, Hereditary Non-polyposis Colon Cancer (hmsh2, hmlh1, hpms1, hpms2)

Start: 2007-07-31End: 2009-08-31Target: 600Updated: 2013-07-10

Phase 4

Postpartum Levonorgestrel-releasing Intrauterine System and Breastfeeding

CompletedNCT01555931

University of North Carolina, Chapel HillPostpartum Contraception

Start: 2012-03-31End: 2013-06-30Updated: 2014-08-25

Unknown Phase

Levonorgestrel-releasing Intrauterine System and Tubal Ligation

TerminatedNCT04663568

Assiut UniversityTubal Ligation

Start: 2020-12-01End: 2021-12-01Updated: 2022-11-30

Adenomyosis and Pregnancy: Levonorgestrel vs. GnRH for Blastocyst Transfer

CompletedNCT06581679

Zagazig UniversityAdenomyosis

Start: 2023-12-15End: 2024-07-01Updated: 2024-09-03

Related Papers

Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial protocol.

2022-11-047 citations